Neo-Adjuvant chemotherapy in the management of appendicular soft tissue sarcomas

1991 ◽  
pp. 362-364
Author(s):  
P. Benedetto ◽  
W. Mnaymneh ◽  
L. Ghandur-Mnaymneh ◽  
M. Joppert ◽  
D. Robinson ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Neo Adjuvant Chemotherapy

A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations.

1986 ◽  
Vol 4 (4) ◽  
pp. 552-558 ◽  
Author(s):  
F Gherlinzoni ◽  
G Bacci ◽  
P Picci ◽  
R Capanna ◽  
P Calderoni ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Local Treatment ◽  
Soft Tissue Sarcomas ◽  
Rank Test ◽  
High Grade ◽  
Chemotherapy Group ◽  
The Difference ◽  
To Receive ◽  
Observation Period

A new trial for evaluating the effectiveness of adjuvant chemotherapy in high-grade soft-tissue sarcomas of the extremities in adult patients is presented. All patients after local treatment were randomized into two arms, one without further therapy and the other to receive adjuvant chemotherapy (Adriamycin [Farmitalia-Carlo Erba, Milan, Italy], 450 mg/m2). The preliminary results of the study are reported at a median observation period of 27.6 months. Of the 59 patients who entered the study, 79.1% in the chemotherapy group are without sign of disease, whereas the corresponding figure in the nonadjuvant chemotherapy group is 54.3%. The difference between the two groups is statistically significant (P less than .005, log rank test). These preliminary observations encourage continuation of the study.

Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma – Authors' reply

2017 ◽  
Vol 18 (11) ◽  
pp. e630 ◽  
Author(s):  
Rolf D Issels ◽  
Lars H Lindner ◽  
Rüdiger Wessalowski ◽  
Ulrich Mansmann
Keyword(s):  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Regional Hyperthermia ◽  
Neo Adjuvant Chemotherapy

Efficacy and safety of administration of gemcitabine and docetaxel with radiation therapy in patients with high-grade soft tissue sarcoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e21503-e21503
Author(s):  
G. G. Raval ◽  
R. Govindarajan
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Tumor Necrosis ◽  
Outpatient Basis ◽  
High Grade ◽  
Time Of Surgery ◽  
Neo Adjuvant Chemotherapy

e21503 Background: Neo-adjuvant therapy of soft tissue sarcoma is not standardized. Anthracyclines (A) improve disease free and overall survival in high grade extremity soft tissue sarcomas measuring more than 5 cm. A and ifosfamide (I) therapy require inpatient administration and is associated with significant toxicities when administered in combination with RT. G in combination with D has been shown to prolong progression free and overall survival in patients with advanced or metastatic STS after progression on A and I, and in patients unable to receive the combination. The safety of administration of G with radiation is not known. We evaluated the safety of neo-adjuvant G and D in combination with RT in patients with STS. Methods: Retrospective analysis of subjects with high grade STS treated with RT and neo-adjuvant chemotherapy with G and D was conducted. G 600mg/m2 was administered on days 1 and 8 along with D 75 mg/m2 on day 8 for a total of 3 cycles. 2200 cGY RT was administered in 11 daily fractions between cycles 1 and 2 and between cycles 2 and 3. 72 hour gap was given between RT and chemotherapy. Chemotherapy was administered on outpatient basis. Efficacy was evaluated by the extent of tumor necrosis at the time of surgery. Safety was evaluated by the presence of complications following chemotherapy. Results: GD + R was administered to 12 patients in the neo-adjuvant setting. 11 of them were evaluable for response. 10 of the 11 patients had evidence of tumor necrosis at the time of surgery. 1 patient had poor response. 3 of 11 patients had neutropenia complicating neo-adjuvant chemotherapy. 4 patients required hospital admission post chemotherapy. 3 for neutopenic fever, and 1 for fever, chills and pneumonia without neutropenia. Conclusions: Gemcitabine and taxotere combination with radiation therapy can be administered safely on outpatient basis with minimal toxicity. Further safety and efficacy evaluation of this therapy will need to be confirmed in a prospective phase II study. No significant financial relationships to disclose.

Management and outcome of patients with neo-adjuvant chemotherapy (CT) in locally advanced soft-tissue sarcoma (LASTS): The Gustave Roussy experience.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 11580-11580
Author(s):  
Sarah Naomie Dumont ◽  
Elena Cojocaru ◽  
Matthieu Faron ◽  
Leila Haddag ◽  
Jean Francois Honart ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Locally Advanced ◽  
Advanced Soft Tissue Sarcoma ◽  
Neo Adjuvant Chemotherapy

scholarly journals Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma

2004 ◽  
Vol 15 (11) ◽  
pp. 1667-1672 ◽  
Author(s):  
S.R. Grobmyer ◽  
R.G. Maki ◽  
G.D. Demetri ◽  
M. Mazumdar ◽  
E. Riedel ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
High Grade ◽  
Extremity Soft Tissue Sarcoma ◽  
Neo Adjuvant Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document